PMID- 30654712
OWN - NLM
STAT- MEDLINE
DCOM- 20200312
LR  - 20200312
IS  - 1557-8534 (Electronic)
IS  - 1547-3287 (Linking)
VI  - 28
IP  - 6
DP  - 2019 Mar 15
TI  - Activin Receptor 2 Antagonization Impairs Adipogenic and Enhances Osteogenic 
      Differentiation in Mouse Adipose-Derived Stem Cells and Mouse Bone Marrow-Derived 
      Stem Cells In Vitro and In Vivo.
PG  - 384-397
LID - 10.1089/scd.2018.0155 [doi]
AB  - Tumors, traumata, burn injuries or surgeries can lead to critical-sized bony 
      defects which need to be reconstructed. Mesenchymal stem cells (MSCs) have the 
      ability to differentiate into multiple cell lineages and thus present a promising 
      alternative for use in tissue engineering and reconstruction. However, there is 
      an ongoing debate whether all MSCs are equivalent in their differentiation and 
      proliferation ability. The goal of this study was to assess osteogenic and 
      adipogenic characteristic changes of adipose-derived stem cells (ASCs) and bone 
      marrow-derived stem cells (BMSCs) upon Myostatin inhibition with Follistatin in 
      vitro and in vivo. We harvested ASCs from mice inguinal fat pads and BMSCs from 
      tibiae of mice. By means of histology, real-time cell analysis, 
      immunohistochemistry, and PCR osteogenic and adipogenic proliferation and 
      differentiation in the presence or absence of Follistatin were analyzed. In vivo, 
      osteogenic capacity was investigated in a tibial defect model of wild-type (WT) 
      mice treated with mASCs and mBMSCs of Myo(-/-) and WT origin. In vitro, we were 
      able to show that inhibition of Myostatin leads to markedly reduced proliferative 
      capacity in mBMSCs and mASCs in adipogenic differentiation and reduced 
      proliferation in osteogenic differentiation in mASCs, whereas proliferation in 
      mBMSCs in osteogenic differentiation was increased. Adipogenic differentiation 
      was inhibited in mASCs and mBMSCs upon Follistatin treatment, whereas osteogenic 
      differentiation was increased in both cell lineages. In vivo, we could 
      demonstrate increased osteoid formation in WT mice treated with mASCs and mBMSCs 
      of Myo(-/-) origin and enhanced osteogenic differentiation and proliferation of 
      mASCs of Myo(-/-) origin. We could demonstrate that the osteogenic potential of 
      mASCs could be raised to a level comparable to mBMSCs upon inhibition of 
      Myostatin. Moreover, Follistatin treatment led to inhibition of adipogenesis in 
      both lineages.
FAU - Wallner, Christoph
AU  - Wallner C
AD  - Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr 
      University Bochum, Bochum, Germany.
FAU - Huber, Julika
AU  - Huber J
AD  - Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr 
      University Bochum, Bochum, Germany.
FAU - Drysch, Marius
AU  - Drysch M
AD  - Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr 
      University Bochum, Bochum, Germany.
FAU - Schmidt, Sonja Verena
AU  - Schmidt SV
AD  - Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr 
      University Bochum, Bochum, Germany.
FAU - Wagner, Johannes Maximilian
AU  - Wagner JM
AD  - Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr 
      University Bochum, Bochum, Germany.
FAU - Dadras, Mehran
AU  - Dadras M
AD  - Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr 
      University Bochum, Bochum, Germany.
FAU - Dittfeld, Stephanie
AU  - Dittfeld S
AD  - Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr 
      University Bochum, Bochum, Germany.
FAU - Becerikli, Mustafa
AU  - Becerikli M
AD  - Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr 
      University Bochum, Bochum, Germany.
FAU - Jaurich, Henriette
AU  - Jaurich H
AD  - Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr 
      University Bochum, Bochum, Germany.
FAU - Lehnhardt, Marcus
AU  - Lehnhardt M
AD  - Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr 
      University Bochum, Bochum, Germany.
FAU - Behr, Bjorn
AU  - Behr B
AD  - Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr 
      University Bochum, Bochum, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190220
PL  - United States
TA  - Stem Cells Dev
JT  - Stem cells and development
JID - 101197107
RN  - 0 (Follistatin)
RN  - EC 2.7.11.30 (Activin Receptors)
SB  - IM
MH  - Activin Receptors/*antagonists & inhibitors/genetics/metabolism
MH  - Adipogenesis/*drug effects/genetics
MH  - Adipose Tissue/cytology/*metabolism
MH  - Animals
MH  - Bone Marrow Cells/cytology/*metabolism
MH  - Cell Differentiation/*drug effects/genetics
MH  - Female
MH  - Follistatin/*pharmacology
MH  - Mice
MH  - Mice, Knockout
MH  - Osteogenesis/*drug effects/genetics
MH  - Stem Cells/cytology/*metabolism
OTO - NOTNLM
OT  - MSC
OT  - adipogenesis
OT  - differentiation
OT  - osteogenesis
EDAT- 2019/01/19 06:00
MHDA- 2020/03/13 06:00
CRDT- 2019/01/19 06:00
PHST- 2019/01/19 06:00 [pubmed]
PHST- 2020/03/13 06:00 [medline]
PHST- 2019/01/19 06:00 [entrez]
AID - 10.1089/scd.2018.0155 [doi]
PST - ppublish
SO  - Stem Cells Dev. 2019 Mar 15;28(6):384-397. doi: 10.1089/scd.2018.0155. Epub 2019 
      Feb 20.